Novartis Announces Positive Results From Late-Stage Study on Fabhalta
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 ...
Novartis reports topline outcomes from Phase IIIB PNH trial of Fabhalta
Novartis has reported positive topline outcomes from the multicentre Phase IIIB APPULSE-PNH trial of oral Fabhalta (iptacopan ...
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...
Nasdaq3d
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
Novartis NVS announced positive top-line results from a late-stage study on Fabhalta (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is an oral, Factor B ...
The Pharma Letter6d
New Phase IIIb data show Novartis Fabhalta improved hemoglobin levels
Novartis today announced positive top-line results from APPULSE-PNH, a Phase IIIb study on the efficacy and safety of ...
Healthline24d
All About Fabhalta
Fabhalta (iptacopan) is a prescription drug that’s used to treat a rare type of kidney disease and a rare blood disorder. Fabhalta comes as an oral capsule that’s typically taken twice per day.
Novartis reports new Phase 3B data for Fabhalta
Novartis (NVS) announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral ...
ENDPOINTS NEWS6d
No­var­tis bol­sters Fab­hal­ta da­ta in com­pe­ti­tion with As­traZeneca
Novartis’ Fabhalta improved hemoglobin levels in patients with a rare blood disorder who switched from anti-C5 therapies, ...